MedTrace Logo

Phase 1 Study of AWT020 in Advanced Cancer

NCT06092580 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-02

No results posted yet for this study

Summary

The aims of this clinical trial are (1) to assess the safety of AWT020 at different dose levels; (2) to determine the pharmacokinetics and pharmacodynamics of AWT020 in subjects with locally advanced or metastatic cancer who have failed standard therapy.

Conditions

Interventions

BIOLOGICAL

AWT020

Participants receiving AWT020 once every two weeks or longer at designated dose levels

Sponsors & Collaborators

  • Anwita Biosciences

    lead INDUSTRY

Principal Investigators

  • Jermaine Coward, BSc (Hons) MBBS MRCP FRACP PhD · Icon Cancer Centre South Brisbane

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06092580 on ClinicalTrials.gov